Cargando…
Drug Conjugation via Maleimide–Thiol Chemistry Does Not Affect Targeting Properties of Cysteine-Containing Anti-FGFR1 Peptibodies
[Image: see text] With a wide range of available cytotoxic therapeutics, the main focus of current cancer research is to deliver them specifically to the cancer cells, minimizing toxicity against healthy tissues. Targeted therapy utilizes different carriers for cytotoxic drugs, combining a targeting...
Autores principales: | Jendryczko, Karolina, Rzeszotko, Jakub, Krzyscik, Mateusz Adam, Kocyła, Anna, Szymczyk, Jakub, Otlewski, Jacek, Szlachcic, Anna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066409/ https://www.ncbi.nlm.nih.gov/pubmed/35389227 http://dx.doi.org/10.1021/acs.molpharmaceut.1c00946 |
Ejemplares similares
-
Peptibody Based on FGFR1-Binding Peptides From the FGF4 Sequence as a Cancer-Targeting Agent
por: Jendryczko, Karolina, et al.
Publicado: (2021) -
FGF2-Derived PeptibodyF2-MMAE Conjugate for Targeted Delivery of Cytotoxic Drugs into Cancer Cells Overexpressing FGFR1
por: Jendryczko, Karolina, et al.
Publicado: (2020) -
The cytotoxic conjugate of highly internalizing tetravalent antibody for targeting FGFR1-overproducing cancer cells
por: Poźniak, Marta, et al.
Publicado: (2021) -
FGFR1 clustering with engineered tetravalent antibody improves the efficiency and modifies the mechanism of receptor internalization
por: Pozniak, Marta, et al.
Publicado: (2020) -
Site-Specific, Stoichiometric-Controlled, PEGylated
Conjugates of Fibroblast Growth Factor 2 (FGF2) with Hydrophilic Auristatin
Y for Highly Selective Killing of Cancer Cells Overproducing Fibroblast
Growth Factor Receptor 1 (FGFR1)
por: Krzyscik, Mateusz Adam, et al.
Publicado: (2020)